Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Shide K, Kameda T, Yamaji T, Sekine M, Inada N, Kamiunten A, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Shimoda H, Kitanaka A, Honda A, Sawaguchi A, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hasuike S, Yamamoto S, Nagata K, Shimoda K. Shide K, et al. Among authors: shimoda h, shimoda k. Leukemia. 2017 May;31(5):1136-1144. doi: 10.1038/leu.2016.308. Epub 2016 Nov 3. Leukemia. 2017. PMID: 27807369 Free PMC article.
TET2 is essential for survival and hematopoietic stem cell homeostasis.
Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Yamamoto S, Miike T, Iwakiri H, Hasuike S, Nagata K, Marutsuka K, Iwama A, Matsuda T, Kitanaka A, Shimoda K. Shide K, et al. Among authors: shimoda h, shimoda k. Leukemia. 2012 Oct;26(10):2216-23. doi: 10.1038/leu.2012.94. Epub 2012 Apr 3. Leukemia. 2012. PMID: 22469782
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y, Shide K, Kameda T, Yamaji T, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hashimoto K, Yamamoto S, Hasuike S, Hidaka T, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: shimoda h, shimoda k. Ann Lab Med. 2017 Mar;37(2):159-161. doi: 10.3343/alm.2017.37.2.159. Ann Lab Med. 2017. PMID: 28029004 Free PMC article. No abstract available.
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K. Shide K, et al. Among authors: shimoda hk, shimoda k. Leukemia. 2008 Jan;22(1):87-95. doi: 10.1038/sj.leu.2405043. Epub 2007 Nov 22. Leukemia. 2008. PMID: 18033315
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Kameda T, et al. Among authors: shimoda h, shimoda k. Blood. 2015 Jan 8;125(2):304-15. doi: 10.1182/blood-2014-04-555508. Epub 2014 Nov 13. Blood. 2015. PMID: 25395421 Free article.
Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A, Shide K, Kameda T, Ito M, Sekine M, Kubuki Y, Hidaka T, Akizuki K, Tahira Y, Toyama T, Kawano N, Marutsuka K, Maeda K, Takeuchi M, Kawano H, Sato S, Ishizaki J, Shimoda H, Yamashita K, Matsuoka H, Shimoda K. Kamiunten A, et al. Among authors: shimoda h, shimoda k. Int J Hematol. 2018 Oct;108(4):411-415. doi: 10.1007/s12185-018-2495-2. Epub 2018 Jul 9. Int J Hematol. 2018. PMID: 29987745
Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K, Taniguchi Y, Sekine M, Kamiunntenn A, Maeda K, Nagata K, Matsunaga T, Shimoda K. Kameda T, et al. Among authors: shimoda hk, shimoda k. Int J Hematol. 2010 Sep;92(2):320-5. doi: 10.1007/s12185-010-0653-2. Epub 2010 Aug 10. Int J Hematol. 2010. PMID: 20697856
TET2 mutation in diffuse large B-cell lymphoma.
Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: shimoda h, shimoda k. J Clin Exp Hematop. 2017;56(3):145-149. doi: 10.3960/jslrt.56.145. J Clin Exp Hematop. 2017. PMID: 28331128 Free PMC article.
367 results